Case Report|Articles in Press

A case of pediatric anti-leucine-rich glioma inactivated 1 encephalitis with faciobrachial dystonic seizure

Published:February 27, 2023DOI:



      Anti-leucine-rich glioma-inactivated 1 (LGI1) encephalitis is a rare type of autoimmune encephalitis. A characteristic faciobrachial dystonic seizure (FBDS) is also frequently associated with this disease. Although primarily reported in the adult population, reports of its occurrence in the pediatric population are rare. Here, we describe a case of a 6-year-old girl diagnosed with anti-LGI1 encephalitis that presented with cognitive decline and FBDS.

      Case presentation

      The girl was referred to a pediatric neurology department for uncontrolled seizures and dyskinesia. She initially presented with a memory deficit, abnormal movement of the limbs and trunk, and ataxia. Her cerebrospinal fluid exam was unremarkable, but her brain MRI showed focal T2 high signal intensity in the left anterior putamen and right caudate nucleus. In addition, there were refractory episodes of brief tonic or dystonic movement of the face and arms that were suggestive of FBDS. She was initially treated with intravenous methylprednisolone and phenobarbital, then given another pulse of methylprednisolone and intravenous immunoglobulin as her symptoms persisted. Tests for neuronal autoantibodies revealed the presence of anti-LGI1 antibodies. Subsequent human leukocyte antigen (HLA) typing resulted in the identification of HLA-DRB1 DR7(*07:01 g) DR9(*09:01 g). Screening for thymoma and other neoplasms showed no signs of a tumor. She was treated with rituximab, tocilizumab, and antiseizure medications, including oxcarbazepine, valproic acid, and lamotrigine. Her FBDS and cognitive symptoms showed substantial improvements.


      While it is known that anti-LGI1 encephalitis responds well to immunotherapy, our patient showed an incomplete response, requiring further therapy. This is the first report of a pediatric patient with anti-LGI1 encephalitis treated with tocilizumab.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Brain and Development
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Lancaster E.
        • Dalmau J.
        Neuronal autoantigens–pathogenesis, associated disorders, and antibody testing.
        Nat Rev Neurol. 2012; 8: 380-390
        • Dalmau J.
        • Geis C.
        • Graus F.
        Autoantibodies to synaptic receptors and neuronal cell surface proteins in autoimmune diseases of the central nervous system.
        Physiol Rev. 2017; 97: 839-887
        • van Sonderen A.
        • Thijs R.D.
        • Coenders E.C.
        • Jiskoot L.C.
        • Sanchez E.
        • de Bruijn M.A.
        • et al.
        Anti-LGI1 encephalitis: Clinical syndrome and long-term follow-up.
        Neurology. 2016; 87: 1449-1456
        • Binks S.
        • Varley J.
        • Lee W.
        • Makuch M.
        • Elliott K.
        • Gelfand J.M.
        • et al.
        Distinct HLA associations of LGI1 and CASPR2-antibody diseases.
        Brain. 2018; 141: 2263-2271
        • Kim T.J.
        • Lee S.T.
        • Moon J.
        • Sunwoo J.S.
        • Byun J.I.
        • Lim J.A.
        • et al.
        Anti-LGI1 encephalitis is associated with unique HLA subtypes.
        Ann Neurol. 2017; 81: 183-192
        • Nosadini M.
        • Toldo I.
        • Tascini B.
        • Bien C.G.
        • Parmeggiani L.
        • De Gaspari P.
        • et al.
        LGI1 and CASPR2 autoimmunity in children: Systematic literature review and report of a young girl with Morvan syndrome.
        J Neuroimmunol. 2019; 335577008
      1. Alotaibi W, Bashir S, Mir A. Faciobrachial Dystonic Seizures as a Sign of Relapse in a Child with LGI-1 Encephalitis. Child Neurol Open. 2022;9:2329048X221105960.

        • Venkatesan A.
        • Benavides D.R.
        Autoimmune encephalitis and its relation to infection.
        Curr Neurol Neurosci Rep. 2015; 15: 3
        • Ohkawa T.
        • Fukata Y.
        • Yamasaki M.
        • Miyazaki T.
        • Yokoi N.
        • Takashima H.
        • et al.
        Autoantibodies to epilepsy-related LGI1 in limbic encephalitis neutralize LGI1-ADAM22 interaction and reduce synaptic AMPA receptors.
        J Neurosci. 2013; 33: 18161-18174
        • Abboud H.
        • Probasco J.C.
        • Irani S.
        • Ances B.
        • Benavides D.R.
        • Bradshaw M.
        • et al.
        Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management.
        J Neurol Neurosurg Psychiatry. 2021; 92: 757-768
        • Arino H.
        • Armangue T.
        • Petit-Pedrol M.
        • Sabater L.
        • Martinez-Hernandez E.
        • Hara M.
        • et al.
        Anti-LGI1-associated cognitive impairment: Presentation and long-term outcome.
        Neurology. 2016; 87: 759-765
        • Lee W.J.
        • Lee S.T.
        • Moon J.
        • Sunwoo J.S.
        • Byun J.I.
        • Lim J.A.
        • et al.
        Tocilizumab in Autoimmune Encephalitis Refractory to Rituximab: An Institutional Cohort Study.
        Neurotherapeutics. 2016; 13: 824-832
        • Jaafar F.
        • Haddad L.
        • Koleilat N.
        • Sharara-Chami R.
        • Shbarou R.
        Super refractory status epilepticus secondary to anti-GAD antibody encephalitis successfully treated with aggressive immunotherapy.
        Epilepsy Behav Rep. 2020; 14100396
        • Randell R.L.
        • Adams A.V.
        • Van Mater H.
        Tocilizumab in Refractory Autoimmune Encephalitis: A Series of Pediatric Cases.
        Pediatr Neurol. 2018; 86: 66-68
        • Aurangzeb S.
        • Symmonds M.
        • Knight R.K.
        • Kennett R.
        • Wehner T.
        • Irani S.R.
        LGI1-antibody encephalitis is characterised by frequent, multifocal clinical and subclinical seizures.
        Seizure. 2017; 50: 14-17
        • Park S.
        • Choi H.
        • Cheon G.J.
        • Wook Kang K.
        • Lee D.S.
        18F-FDG PET/CT in anti-LGI1 encephalitis: initial and follow-up findings.
        Clin Nucl Med. 2015; 40: 156-158
        • Liu X.
        • Shan W.
        • Zhao X.
        • Ren J.
        • Ren G.
        • Chen C.
        • et al.
        The Clinical Value of (18) F-FDG-PET in Autoimmune Encephalitis Associated With LGI1 Antibody.
        Front Neurol. 2020; 11: 418